Peptides DB
Research-centric peptide and protocol reference hub
Study 20 of 23MOTS-C literatureJournal of ethnopharmacology · Animal study · Preclinical2026

Guizhi Wuling Decoction alleviates myocardial fibrosis by restoring mitochondrial homeostasis: Evidence from network pharmacology, molecular docking, and multi-omics integration.

Guizhi Wuling Decoction may alleviate myocardial fibrosis in mice by restoring mitochondrial homeostasis via AMPK/PGC-1α signaling, but human relevance is unproven.

Read at Journal of ethnopharmacologyAdd to compare

Where it sits

this study against the rest of the mots-c corpus
12
Preclinical · this one
9
Observational
0
Open-label
1
Randomised
1
Reviews

Summary and findings

The study evaluated the effects of Guizhi Wuling Decoction (GWD) on myocardial fibrosis in C57BL/6J mice induced by isoproterenol. GWD improved cardiac function and mitochondrial homeostasis, potentially through the AMPK/PGC-1α signaling pathway. Pharmacological inhibition of AMPK attenuated these effects.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.Preclinical2026

Abstract

The authors’ words, as Journal of ethnopharmacology supplied them

<h4>Ethnopharmacological relevance</h4>Guizhi Wuling Decoction (GWD), a combined prescription consisting of the classical formulas Wuling San and Guizhi Fuling Wan without modification, has been clinically applied for cardiovascular diseases. Previous studies have reported its cardioprotective and anti-fibrotic effects; however, the underlying molecular mechanisms remain incompletely understood.<h4>Aim of the study</h4>To investigate whether restoration of mitochondrial homeostasis contributes to the anti-fibrotic effects of GWD and to explore the involvement of AMPK/PGC-1α signaling.<h4>Materials and methods</h4>Myocardial fibrosis (MF) was induced in C57BL/6 J mice by isoproterenol (ISO) administration. Cardiac function, myocardial fibrosis, mitochondrial ultrastructure, mitochondrial membrane potential, ATP production, and NAD+/NADH ratio were evaluated. Absorbed constituents in GWD-containing serum were characterized using UHPLC-MS/MS. Integrated transcriptomic-proteomic analysis highlighted AMPK signaling as one of the important pathways associated with GWD treatment. Molecular docking and molecular dynamics simulations were conducted to evaluate the interactions between representative absorbed compounds and candidate targets. The involvement of AMPK signaling was further validated by pharmacological inhibition using Compound C.<h4>Results</h4>GWD significantly improved cardiac function, attenuated myocardial fibrosis, and restored mitochondrial homeostasis, as evidenced by improved mitochondrial ultrastructure, increased mitochondrial membrane potential, ATP production, and NAD+/NADH ratio. Integrated transcriptomic and proteomic analyses identified AMPK signaling as an important pathway associated with the protective effects of GWD. Mechanistically, GWD activated the AMPK/PGC-1α signaling pathway and upregulated mitochondrial biogenesis- and quality control-related proteins, including NRF1, TFAM, and MFN2. Pharmacological inhibition of AMPK by Compound C significantly attenuated GWD-associated improvement of mitochondrial homeostasis and anti-fibrotic effects.<h4>Conclusion</h4>GWD alleviates ISO-induced MF, at least in part, by restoring mitochondrial homeostasis. Integrated multi-omics analyses and pharmacological validation suggest that AMPK/PGC-1α signaling may contribute to the anti-fibrotic effects of GWD. These findings provide experimental evidence suggesting the involvement of mitochondrial homeostasis in MF and offer new insights into the anti-fibrotic effects of GWD.

Background

Myocardial fibrosis is a significant contributor to cardiovascular diseases, and there is interest in exploring traditional remedies like Guizhi Wuling Decoction (GWD) for their potential therapeutic effects. Previous studies have suggested cardioprotective and anti-fibrotic effects of GWD, but the molecular mechanisms remain unclear. This study aims to elucidate whether mitochondrial homeostasis plays a role in GWD's anti-fibrotic effects, focusing on the AMPK/PGC-1α signaling pathway.

Methods

The study used C57BL/6J mice with myocardial fibrosis induced by isoproterenol administration. GWD's effects on cardiac function, myocardial fibrosis, mitochondrial ultrastructure, membrane potential, ATP production, and NAD+/NADH ratio were assessed. UHPLC-MS/MS characterized absorbed constituents in GWD-containing serum. Transcriptomic-proteomic analysis and molecular docking evaluated AMPK signaling involvement, with pharmacological validation using Compound C.

Results

GWD treatment significantly improved cardiac function and reduced myocardial fibrosis in the mouse model. Mitochondrial homeostasis was restored, as indicated by improved ultrastructure, increased membrane potential, ATP production, and NAD+/NADH ratio. AMPK signaling was identified as a key pathway, with GWD activating the AMPK/PGC-1α pathway and upregulating mitochondrial biogenesis proteins. Inhibition of AMPK by Compound C reduced these beneficial effects.

Interpretation

The study suggests that GWD may exert its anti-fibrotic effects through the restoration of mitochondrial homeostasis, mediated by the AMPK/PGC-1α signaling pathway. While the findings are promising, they are limited to an animal model, and the clinical significance in humans remains uncertain. The lack of quantitative data in the abstract also limits the ability to assess the magnitude of the effects.

Key findings

  • GWD significantly improved cardiac function in ISO-induced myocardial fibrosis.
  • GWD restored mitochondrial ultrastructure and increased mitochondrial membrane potential.
  • ATP production and NAD+/NADH ratio were increased with GWD treatment.
  • AMPK signaling was identified as an important pathway in GWD's effects.
  • Pharmacological inhibition of AMPK reduced GWD's benefits on mitochondrial homeostasis.

Limitations

  • animal model only, no human data
  • lack of quantitative effect sizes in abstract
  • mechanistic focus, not clinical outcomes

Elsewhere in the MOTS-C corpus

CTubuloside A mitigates sepsis-induced splenic injury in mice by suppressing NOX4-associated oxidative stress, inflammation, apoptosis, and mitochondrial dysfunction.Journal of ethnopharmacology · 2026 · TA significantly alleviated splenic injury and improved survival in septic mice.AnimalCKunkui Baoshen Granule attenuates diabetic kidney disease via the SIRT3/FOXO3a signaling pathway: An integrated multi-omics analysis.Journal of ethnopharmacology · 2026 · Not reported in abstract.AnimalCSan-Wei-Du-Juan formula ameliorates hypoxic lung injury by regulating the MAPK signaling pathway.Journal of ethnopharmacology · 2026 · 32.5% reduction in lung wet/dry weight.AnimalCPolydatin improves mitochondrial dynamics dysrhythmia by regulating BMAL1 to prevent and treat metabolic dysfunction-associated fatty liver disease.Journal of ethnopharmacology · 2026 · Not reported in abstract.AnimalCMailuo Shutong pills alleviate limb swelling in femoral fracture rats by orchestrating mitophagic clearance and ferroptotic suppression.Journal of ethnopharmacology · 2026 · Not reported in abstract.AnimalCMethylophiopogonanone A mitigates myocardial ischemia-reperfusion injury: involvement of VEGFR2-associated PI3K/Akt/GSK-3β signaling and suppression of mPTP opening.Journal of ethnopharmacology · 2026 · MOA reduced infarct size and improved cardiac function in vivo.Animal